This is a working overview of MC1R, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
== Ecology == The Rotheca myricoides interacts with several other species. Pseumenes depressus, the Asian hornet, and Xylocopa ruficeps all visit the Rotheca myricoides. Xylocopa phalothorax, Xylocopa tranquebarorum, and Xylocopa nasalis eat the Rotheca myricoides. The plant plays a significant role in its native ecosystems by supporting pollinators like butterflie and bees. Its long corolla tubes are adapted to attract specific pollinators with long proboscises for effective pollen transfer. The plant provides food to birds that consume its drupes, helping in seed dispersal. The status on the Red List of South African plants is at "Least Concern" as assessed on 2005/06/30, as it was not highlighted as a potential taxa for conservation concern.
. The four approaches deliver slightly different information. Although the results of clamp-, IVGTT-, OGTT- and SPINA-derived disposition indices significantly correlate with each other the correlations are only modest. In direct comparison, the SPINA-based disposition index (SPINA-DI) had higher discriminatory power for the diagnosis of diabetes than the OGTT-based disposition index according to Matsuda and DeFronzo.
While working at St Mary's Hospital, London in 1928, Alexander Fleming, a Scottish physician, was investigating the variation of growth in cultures of S. aureus, trying to replicate research from Trinity College Dublin. He spent the summer break with his family at his country home The Dhoon at Barton Mills, Suffolk. Before leaving his laboratory at the end of July, he inoculated several culture plates with S. aureus. He kept the plates aside on one corner of the table away from direct sunlight and to make space for his research student, Stuart Craddock, to work in his absence. He returned to his laboratory on 3 September. As he and Daniel Merlin Pryce, his former research student, examined the culture plates, they found one with an open lid and the culture contaminated with a blue-green mould. In the contaminated plate the bacteria around the mould did not grow, while those farther away grew normally, meaning that the mould killed the bacteria. Fleming photographed the culture and took a sample of the mould for identification. Fleming resumed his vacation and returned to St Mary's that month. He collected the original mould and grew it in culture plates. After four days he found that the plates developed large colonies of the mould. He repeated the experiment with the same bacteria-killing results. He concluded that the mould was releasing a substance that was inhibiting bacterial growth. On testing against different bacteria, he found that the mould could kill only certain Gram-positive bacteria.
Sources: en.wikipedia.org
=== Competition and other plant symbionts === Competition among EcM fungi is a well-documented case of soil microbial interactions. In some experiments, the timing of colonization by competing EcM fungi determined which species was dominant. Many biotic and abiotic factors can mediate competition among EcM fungi, such as temperature, soil pH, soil moisture, host specificity, and competitor number, and these factors interact with each other in a complex way. There is also some evidence for competition between EcM fungi and arbuscular mycorrhizal fungi. This is mostly noted in species that can host both EcM and AM fungi on their roots. Some soil bacteria, known as Mycorrhiza helper bacteria (MHBs), have been shown to stimulate EcM formation, root and shoot biomass, and fungal growth. Some argue that bacteria of this kind should be considered a third component of mycorrhizas. Other bacteria inhibit ectomycorrhizal formation.
It separately killed Davoud Alizadeh, the commander of the Quds Force's Lebanon Corps, in Tehran. In the night, Hezbollah fired rockets at Tel Aviv and Haifa. By 4 March, more than 300,000 southern Lebanese residents had been displaced due to the conflict. Israeli strikes hit residential areas in Beirut and eastern Lebanon, killing at least 11 people. Two Israeli soldiers were wounded in Lebanon after Hezbollah claimed to have struck a Merkava tank in Houla. On 6 March, a Hezbollah rocket strike in northern Israel injured eight soldiers, five seriously. Later that night, Israeli commandos raided Al-Nabi Shayth in an attempt to recover the remains of missing pilot Ron Arad, leading to a gunbattle that left three Lebanese soldiers dead. Simultaneous airstrikes in the area killed 41 people and injured 40 more. The Israelis withdrew without finding Arad's body. On 8 March, two Israeli soldiers were killed in a separate rocket attack in southern Lebanon. The following day, Hezbollah missiles struck a satellite communications center near Beit Shemesh and a daycare in Ramla in central Israel. On 1 April, an Israeli naval strike in Beirut killed Haj Youssef Ismail Hashem, the commander of Hezbollah's Southern Front. On 8 April, Israeli strikes killed 254 people and wounded more than 1,000 others in central Beirut. Israel Katz said that the strikes targeted hundreds of Hezbollah militants and command centers across Lebanon, in the group's largest blow since the pager attacks. On 16 April, President Trump announced that Israel and Lebanon agreed to a 10-day truce.
The process of selecting appropriate deep final repositories for high-level waste and spent fuel is now underway in several countries with the first expected to be commissioned sometime after 2010. The basic concept is to locate a large, stable geologic formation and use mining technology to excavate a tunnel, or use large-bore tunnel boring machines (similar to those used to drill the Channel Tunnel from England to France) to drill a shaft 500 to 1,000 metres (1,600 to 3,300 ft) below the surface where rooms or vaults can be excavated for disposal of high-level radioactive waste. The goal is to permanently isolate nuclear waste from the human environment. Many people remain uncomfortable with the immediate stewardship cessation of this disposal system, suggesting perpetual management and monitoring would be more prudent. Because some radioactive species have half-lives longer than one million years, even very low container leakage and radionuclide migration rates must be taken into account. Moreover, it may require more than one half-life until some nuclear materials lose enough radioactivity to cease being lethal to living things. A 1983 review of the Swedish radioactive waste disposal program by the National Academy of Sciences found that country's estimate of several hundred thousand years—perhaps up to one million years—being necessary for waste isolation "fully justified." The proposed land-based subductive waste disposal method disposes of nuclear waste in a subduction zone accessed from land and therefore is not prohibited by international agreement.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.